纳武利尤单抗联合伊匹木单抗对比化疗一线治疗PD-L1≥1%晚期NSCLC的患者报告结局:CheckMate 227第1部分
CheckMate 227第1部分中,PD-L1≥1%的晚期NSCLC患者随机接受纳武利尤单抗联合伊匹木单抗、纳武利尤单抗或化疗。患者报告结局显示,联合组在LCSS症状负担和总体健康状况方面从第24周和第30周起达到或超过最小重要差异,且至首次恶化时间延迟(HR 0.74,95%CI 0.56-0.98),而化疗组改善通常低于最小重要差异。
要点
- 联合组LCSS症状负担和总体健康从第24/30周起达到或超过最小重要差异。
- 联合组至首次恶化时间延迟,HR 0.74(95%CI 0.56-0.98)。
- 联合组至首次改善时间有更快趋势,HR 1.24(95%CI 0.98-1.59)。
核心结论
- 在PD-L1≥1%的晚期NSCLC患者中,纳武利尤单抗联合伊匹木单抗对比化疗延迟了症状和健康相关生活质量的恶化,并显示数值上的改善。
研究设计与样本
- CheckMate 227(NCT02477826)第1部分,纳入1189例初治IV期或复发NSCLC且肿瘤PD-L1≥1%的患者,随机接受纳武利尤单抗联合伊匹木单抗、纳武利尤单抗或化疗,患者报告结局为探索性分析。
主要发现
- 患者报告结局完成率通常大于80%。
- 联合组LCSS平均症状负担指数和3项总体指数从基线改善在第24周和第30周起通常达到或超过最小重要差异,化疗组改善通常低于最小重要差异。
- 两治疗组第24周EQ-5D VAS平均评分接近英国人群常模,并在整个治疗期间保持。
- 混合效应模型重复测量分析显示,联合组对比化疗在LCSS平均症状负担指数、3项总体指数、EQ-5D VAS和效用指数上数值改善更大。
- 联合组对比化疗至首次恶化时间延迟(HR 0.74,95%CI 0.56-0.98),至首次改善时间有更快趋势(HR 1.24,95%CI 0.98-1.59)。
临床怎么用
- 对于PD-L1≥1%的晚期NSCLC患者,纳武利尤单抗联合伊匹木单抗一线治疗可延缓症状和生活质量恶化,支持其作为治疗选择。
局限性
- 患者报告结局为探索性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In CheckMate 227 (NCT02477826), patients with treatment-naive stage IV or recurrent NSCLC and 1% or greater tumor programmed death ligand 1 expression had significantly improved overall survival with nivolumab plus ipilimumab versus chemotherapy. We present the patient-reported outcomes (PROs). METHODS: Patients (N = 1189) were randomized to nivolumab plus ipilimumab, nivolumab, or chemotherapy. PROs were exploratory. Changes in Lung Cancer Symptom Scale (LCSS) average symptom burden index, LCSS 3-item global index, EQ-5D visual analog scale (VAS), and EQ-5D utility index were analyzed descriptively. Mixed-effect model repeated measures and time-to-first deterioration and improvement analyses were conducted. RESULTS: PRO completion rates were generally greater than 80%. On-treatment improvements from baseline in LCSS measures of symptom burden and global health status with nivolumab plus ipilimumab generally met or exceeded the minimal important difference (smallest clinically meaningful change) from weeks 24 and 30, respectively; improvements with chemotherapy generally remained below the minimal important difference. Mean on-treatment EQ-5D VAS scores for both treatments approached the U.K. population norm at week 24, remaining so throughout the treatment period. Mixed-effect model repeated measures analyses revealed numerically greater improvements from baseline with nivolumab plus ipilimumab versus chemotherapy across LCSS average symptom burden index and 3-item global index, and EQ-5D VAS and utility index. Nivolumab plus ipilimumab had delayed time-to-first deterioration (hazard ratio [95% confidence interval] 0.74 [0.56 to 0.98]) and a trend for more rapid time-to-first improvement (1.24 [0.98 to 1.59]) versus chemotherapy. CONCLUSIONS: Nivolumab plus ipilimumab revealed delayed deterioration and numerical improvement in symptoms and health-related quality of life versus chemotherapy in patients with advanced NSCLC and 1% or greater programmed death ligand 1 expression.
引用
- Reck M, Ciuleanu TE, Lee JS, et al. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1. J Thorac Oncol. 2021. PMID: 33485960. doi:10.1016/j.jtho.2020.12.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。